BeiGene Ltd (BEIGF)
12.58
0.00 (0.00%)
USD |
OTCM |
Jun 20, 16:00
BeiGene Enterprise Value: 15.46B for June 20, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
June 20, 2024 | 15.46B |
June 18, 2024 | 15.46B |
June 17, 2024 | 15.44B |
June 14, 2024 | 15.33B |
June 13, 2024 | 15.33B |
June 12, 2024 | 15.33B |
June 11, 2024 | 15.33B |
June 10, 2024 | 15.33B |
June 07, 2024 | 15.33B |
June 06, 2024 | 15.33B |
June 05, 2024 | 15.33B |
June 04, 2024 | 15.33B |
June 03, 2024 | 15.33B |
May 31, 2024 | 15.33B |
May 30, 2024 | 15.33B |
May 29, 2024 | 15.33B |
May 28, 2024 | 15.33B |
May 24, 2024 | 15.33B |
May 23, 2024 | 15.33B |
May 22, 2024 | 15.33B |
May 21, 2024 | 15.33B |
May 20, 2024 | 15.33B |
May 17, 2024 | 15.33B |
May 16, 2024 | 15.33B |
May 15, 2024 | 15.33B |
Date | Value |
---|---|
May 14, 2024 | 15.33B |
May 13, 2024 | 15.33B |
May 10, 2024 | 15.33B |
May 09, 2024 | 15.33B |
May 08, 2024 | 15.33B |
May 07, 2024 | 15.33B |
May 06, 2024 | 13.18B |
May 03, 2024 | 13.18B |
May 02, 2024 | 13.18B |
May 01, 2024 | 13.18B |
April 30, 2024 | 13.18B |
April 29, 2024 | 13.18B |
April 26, 2024 | 13.19B |
April 25, 2024 | 13.19B |
April 24, 2024 | 13.19B |
April 23, 2024 | 13.19B |
April 22, 2024 | 13.19B |
April 19, 2024 | 13.19B |
April 18, 2024 | 13.17B |
April 17, 2024 | 13.17B |
April 16, 2024 | 13.17B |
April 15, 2024 | 13.17B |
April 12, 2024 | 13.17B |
April 11, 2024 | 17.64B |
April 10, 2024 | 17.64B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
13.17B
Minimum
Apr 12 2024
20.21B
Maximum
Aug 18 2023
16.40B
Average
16.78B
Median
Nov 06 2023
Enterprise Value Benchmarks
Theravance Biopharma Inc | 321.19M |
LumiraDx Ltd | -- |
CEL-SCI Corp | 61.31M |
AIM ImmunoTech Inc | 12.50M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -251.15M |
Revenue (Quarterly) | 751.65M |
Total Expenses (Quarterly) | 1.013B |
EPS Diluted (Quarterly) | -0.19 |
Gross Profit Margin (Quarterly) | 83.38% |
Profit Margin (Quarterly) | -33.41% |
Earnings Yield | -4.69% |
Normalized Earnings Yield | -4.69 |